Back to News
Market Impact: 0.2
MAIA Biotechnology Board Member, CEO Buy Shares Amid Phase 3 NSCLC Studies
Source: Nasdaq
Healthcare & BiotechInsider TransactionsManagement & Governance
MAIA Biotechnology disclosed insider purchases by board member Ramiro Guerrero and founder/CEO Vlad Vitoc, increasing their ownership stakes in the clinical-stage immune-oncology company. The buying signals management and board confidence, but the article provides no transaction values, share counts, clinical data, or operational updates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MAIA0.45
More News
- Analysis: How Trump could reignite the Fed independence fight after Warsh's rate hike
- DST Global Advisors, 10% owner, sells $109.3m Chime stock
- DST Global Advisors sells $109.3m in Chime Financial shares
- Snap tries to make the case again for its $2,200 smart glasses
- Premarket movers: Intel jumps on SK Hynix memory-chip talks, J.B. Hunt slides
- Snowflake SVP Vivek Raghunathan sells $1.23m in company stock